NCT07094464View on ClinicalTrials.gov

Maintenance Therapy With Selinexor and Azacitidine in TP53 Mutant AML/MDS After Transplantation

PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 1, 2025

Primary Completion Date

June 30, 2027

Study Completion Date

December 30, 2028

Conditions
TP53-mutated MDS and AMLAllogeneic Hematopoietic Stem Cell Transplantation
Interventions
DRUG

Maintenance Therapy with Selinexor and Azacitidine

"1. Selinexor: Oral administration in 4 cycles:~ \- Dose Escalation Phase: Cohort 1: Selinexor, 20 mg, twice a week for 2 weeks Cohort 2: Selinexor, 40 mg, twice a week for 2 weeks Cohort 3: Selinexor, 60 mg, twice a week for 2 weeks~ \- Dose Expansion: MTD/RP2D will be determined based on safety.~2. Azacitidine: 35 mg/m² for 5 days."

Trial Locations (1)

100853

Chinese PLA General Hospital, Beijing

All Listed Sponsors
lead

Daihong Liu

OTHER